Publicaciones en las que colabora con ARANTXA ISLA RUIZ (18)

2023

  1. Ceftaroline and Avibactam Removal by Continuous Renal Replacement Therapies: An in vitro Study

    Blood Purification, Vol. 52, Núm. 5, pp. 464-473

2022

  1. Optimization of levetiracetam dosing regimen in critically ill patients with augmented renal clearance: a Monte Carlo simulation study

    Journal of Intensive Care, Vol. 10, Núm. 1

2021

  1. Population pharmacokinetics of levetiracetam and dosing evaluation in critically ill patients with normal or augmented renal function

    Pharmaceutics, Vol. 13, Núm. 10

  2. Quantification of ceftaroline in human plasma using high‐performance liquid chromatography with ultraviolet detection: Application to pharmacokinetic studies

    Pharmaceutics, Vol. 13, Núm. 7

2020

  1. Impact of augmented renal clearance on the pharmacokinetics of linezolid: Advantages of continuous infusion from a pharmacokinetic/pharmacodynamic perspective

    International Journal of Infectious Diseases, Vol. 93, pp. 329-338

  2. Novel population pharmacokinetic model for linezolid in critically ill patients and evaluation of the adequacy of the current dosing recommendation

    Pharmaceutics, Vol. 12, Núm. 1

2019

  1. Pharmacokinetics of linezolid in critically ill patients on continuous renal replacement therapy: Influence of residual renal function on PK/PD target attainment

    Journal of Critical Care, Vol. 50, pp. 69-76

2018

  1. Population pharmacokinetics of daptomycin in critically ill patients

    International Journal of Antimicrobial Agents, Vol. 52, Núm. 2, pp. 158-165

2014

  1. Population pharmacokinetics of piperacillin and tazobactam in critically ill patients undergoing continuous renal replacement therapy: Application to pharmacokinetic/pharmacodynamic analysis

    Journal of Antimicrobial Chemotherapy, Vol. 69, Núm. 1, pp. 180-189

2008

  1. Population pharmacokinetics of meropenem in critically ill patients undergoing continuous renal replacement therapy

    Clinical Pharmacokinetics, Vol. 47, Núm. 3, pp. 173-180

2007

  1. In vitro AN69 and polysulphone membrane permeability to ceftazidime and in vivo pharmacokinetics during continuous renal replacement therapies

    Chemotherapy, Vol. 53, Núm. 3, pp. 194-201

2006

  1. Elimination of piperacillin and tazobactam by renal replacement therapies with AN69 and polysulfone hemofilters: Evaluation of the sieving coefficient

    Blood Purification, Vol. 24, Núm. 4, pp. 347-354

2005

  1. Cefepime and continuous renal replacement therapy (CRRT): In vitro permeability of two CRRT membranes and pharmacokinetics in four critically ill patients

    Clinical Therapeutics, Vol. 27, Núm. 5, pp. 599-608

  2. Determination of ceftazidime and cefepime in plasma and dialysate-ultrafiltrate from patients undergoing continuous veno-venous hemodiafiltration by HPLC

    Journal of Pharmaceutical and Biomedical Analysis, Vol. 39, Núm. 5, pp. 996-1005

  3. In vitro and in vivo evaluation of enoxaparin removal by continuous renal replacement therapies with acrylonitrile and polysulfone membranes

    Clinical Therapeutics, Vol. 27, Núm. 9, pp. 1444-1451

  4. Influence of renal function on the pharmacokinetics of piperacillin/ tazobactam in intensive care unit patients during continuous venovenous hemofiltration

    Journal of Clinical Pharmacology, Vol. 45, Núm. 2, pp. 168-176

  5. Meropenem and continuous renal replacement therapy: In vitro permeability of 2 continuous renal replacement therapy membranes and influence of patient renal function on the pharmacokinetics in critically ill patients

    Journal of Clinical Pharmacology, Vol. 45, Núm. 11, pp. 1294-1304

  6. Quantification and stability of piperacillin and tazobactam in plasma and ultrafiltrate from patients undergoing continuous venovenous hemofiltration by HPLC

    Biomedical Chromatography, Vol. 19, Núm. 8, pp. 570-578